Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Quarterly Financials

Values in thousands2026-09-302026-06-302026-03-312025-12-31
Revenue
$5,115,800
$4,290,700
$3,605,400
$3,884,300
Gross Profit
4,542,200
3,714,200
2,936,000
3,299,700
EBITDA
2,415,700
1,662,500
967,300
1,200,900
EBIT
2,294,700
1,538,800
844,100
1,055,900
Net Income
1,948,700
1,296,900
727,200
844,600
Net Change In Cash
5,115,800
4,290,700
3,605,400
3,884,300
Free Cash Flow
1,483,200
334,300
848,300
922,000
Cash
3,659,100
2,455,800
2,962,600
3,118,100
Basic Shares
105,600
106,800
107,700
107,500

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$14,342,900
$14,202,000
$13,117,200
$12,172,900
Gross Profit
12,242,200
12,231,500
12,233,500
10,467,700
EBITDA
5,818,200
5,318,000
4,047,100
5,259,600
EBIT
5,274,500
4,835,100
4,047,100
4,918,200
Net Income
4,504,900
4,412,600
3,953,600
4,338,400
Net Change In Cash
14,342,900
14,202,000
13,117,200
12,172,900
Cost of Revenue
221,300
Free Cash Flow
4,080,500
3,664,600
3,667,600
4,424,800
Cash
3,118,100
2,488,200
2,730,000
3,105,900
Basic Shares
108,600
115,100
113,700
113,500

Earnings Calls

QuarterEPS
2026-09-30
$18.43
2026-06-30
$12.53
2026-03-31
$9.47
2025-12-31
$11.44